Zeaxanthin
Zeaxanthin is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
83 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 2 | 1 | 1 | 2 | 25 | 30 |
| Glaucoma | D005901 | EFO_0000516 | H40 | 1 | 1 | — | 1 | 2 | 4 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | — | — | 1 | 1 | 2 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | 2 | 1 | — | 4 | 7 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | 2 | 2 | — | 3 | 7 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | — | 1 | — | 3 | 4 |
| Mitochondrial diseases | D028361 | EFO_0000591 | — | — | 1 | 1 | — | — | 2 |
| Cataract | D002386 | HP_0000518 | H26.9 | — | — | 2 | — | — | 2 |
| Epiretinal membrane | D019773 | HP_0100014 | — | — | — | 1 | — | — | 1 |
| Retinal perforations | D012167 | EFO_1001028 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | — | 3 | 4 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | — | — | 1 | 2 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | 2 | — | — | — | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | 1 | 2 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | — | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | — | — | — | 1 |
| Pregnancy rate | D018873 | — | — | — | 1 | — | — | — | 1 |
| Central serous chorioretinopathy | D056833 | — | H35.71 | — | 1 | — | — | — | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
| Tinnitus | D014012 | HP_0000360 | H93.1 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | — | — | 4 | 4 |
| Syndrome | D013577 | — | — | — | — | — | — | 3 | 3 |
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | — | — | — | — | 3 | 3 |
| Dry eye syndromes | D015352 | — | H04.12 | — | — | — | — | 3 | 3 |
| Wet macular degeneration | D057135 | EFO_0004683 | — | — | — | — | — | 2 | 2 |
| Hyperlipoproteinemias | D006951 | HP_0010980 | — | — | — | — | — | 2 | 2 |
| Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | — | — | — | — | 2 | 2 |
| Cognition | D003071 | EFO_0003925 | — | — | — | — | — | 2 | 2 |
| Macular edema | D008269 | — | — | — | — | — | — | 1 | 1 |
| Edema | D004487 | HP_0000969 | R60.9 | — | — | — | — | 1 | 1 |
Show 31 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Zeaxanthin |
| INN | — |
| Description | Zeaxanthin is a carotenol. It has a role as a bacterial metabolite, a cofactor and an antioxidant. It derives from a hydride of a beta-carotene. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C[C@@H](O)CC2(C)C)C(C)(C)C[C@H](O)C1 |
Identifiers
| PDB | — |
| CAS-ID | 144-68-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2359248 |
| ChEBI ID | 27547 |
| PubChem CID | 5280899 |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
371 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use